Skip to main content
Paradoxical PsO (PP) studied in 2867 RA & 5316 SpA pts. 136 (1.7%) had paradox. Rxn, median 12 mos post TNFi [pust

Dr. John Cush RheumNow

3 years 2 months ago
Paradoxical PsO (PP) studied in 2867 RA & 5316 SpA pts. 136 (1.7%) had paradox. Rxn, median 12 mos post TNFi [pustular (60%) or palmoplantar (31%)]. 73% PP favorably switched to other TNFi 46% or non-TNFi 27%. RA PP took SSZ, HCQ, LEF; SpA PP more smokers https://t.co/w1EQEvHbeG https://t.co/aAwKxdNYk1
Paradoxical Psoriasis in Kids Taking TNF Inhibitors

A multicenter cohort study reported a large cohort of pediatric pa

Dr. John Cush RheumNow

3 years 2 months ago
Paradoxical Psoriasis in Kids Taking TNF Inhibitors A multicenter cohort study reported a large cohort of pediatric patients receiving TNF inhibitor therapy complicated by psoriasis, regardless of treatment indication or the specific TNF inhibitor. https://t.co/9WxkAt8NnS https://t.co/sGvb1eZWE0
TitAIN Study: Secukinumab Efficacy in Giant Cell Arteritis

A phase 2 trial has demonstrated the efficacy of secukinuma

Dr. John Cush RheumNow

3 years 2 months ago
TitAIN Study: Secukinumab Efficacy in Giant Cell Arteritis A phase 2 trial has demonstrated the efficacy of secukinumab, an anti-interleukin-17A monoclonal antibody, in patients with active giant cell arteritis (GCA). https://t.co/rmYBXBV3RP https://t.co/q1CfhuGSj7
Belimumab in adult inflamm myositis (IIM)? Small study 15 IIM pts recv ≥ 5 doses of belimumab or placebo; Treatment su

Dr. John Cush RheumNow

3 years 2 months ago
Belimumab in adult inflamm myositis (IIM)? Small study 15 IIM pts recv ≥ 5 doses of belimumab or placebo; Treatment success (TIS ≥ 40) was more common with BEL (55% vs 33%) as was defined improvement (DOI: 33% vs 17%); not signif, but interesting! https://t.co/3xL0ylJbcs https://t.co/Oerf0yI4Jg
FDA has approved a 2nd JAK inhibitor for Alopecia areata - Pfizers Ritlecitinib (Litfulo) is approved for Adults and Ado

Dr. John Cush RheumNow

3 years 2 months ago
FDA has approved a 2nd JAK inhibitor for Alopecia areata - Pfizers Ritlecitinib (Litfulo) is approved for Adults and Adolescents (>12 yrs) With Severe Alopecia Areata (based on ALLEGRO trial, pub in Lancet) https://t.co/Uods58glJG https://t.co/Uods58glJG https://t.co/syCqnG6sLg
PRE-CLINICAL RA: What do you need to better manage pre-clinical (at-risk) Rheumatoid arthritis Patients? Rheumatologists

Dr. John Cush RheumNow

3 years 2 months ago
PRE-CLINICAL RA: What do you need to better manage pre-clinical (at-risk) Rheumatoid arthritis Patients? Rheumatologists vote here >>https://t.co/lt38vJMEIA
RheumNow’s new Poster Hall features sponsor-generated clinical trial posters designed to educate and inform. Posters a

Dr. John Cush RheumNow

3 years 2 months ago
RheumNow’s new Poster Hall features sponsor-generated clinical trial posters designed to educate and inform. Posters addressing vasculitis, AxSpa and nrAxSpa, and PMR now available. https://t.co/38foNET3j4 https://t.co/8CjXwzyGab
In pts seeking care for MSK pain cannot assume that improving pain/function will result in improved depression, but subs

Dr. John Cush RheumNow

3 years 2 months ago
In pts seeking care for MSK pain cannot assume that improving pain/function will result in improved depression, but substantial improvements are required to effect anxiety. Study of 11 236 Ortho pts in JAMA https://t.co/5vvoPs31GU https://t.co/gEwZNW35xB
Study of FDA review times for New Indication Approvals of Drugs and Biologics (2017 - 2019) finds FDA approved 107 drugs

Dr. John Cush RheumNow

3 years 2 months ago
Study of FDA review times for New Indication Approvals of Drugs and Biologics (2017 - 2019) finds FDA approved 107 drugs for 146 new indications [99 small molecules (68%) & 47 biologics (32%)]. Median regulatory review time was 6 mos (IQR, 6-10) https://t.co/3P6T4R4FCF https://t.co/avl65W3kvr
UK MHRA reminder that NSAIDs are:
- contraindicated in the 3rd trimester of pregnancy (>28wks)
- >20 wks - assoc w

Dr. John Cush RheumNow

3 years 2 months ago
UK MHRA reminder that NSAIDs are: - contraindicated in the 3rd trimester of pregnancy (>28wks) - >20 wks - assoc w/ increased risk of oligohydramnios & fetal renal dysfunction MDs should avoid NSAIDs in pregnancy after wk 20 https://t.co/u3fTnuoF17 https://t.co/b2b5XThe1i
Predictors of Cardiovascular Events in ANCA-Associated Vasculitis

A large, retrospective, multinational study of patie

Dr. John Cush RheumNow

3 years 2 months ago
Predictors of Cardiovascular Events in ANCA-Associated Vasculitis A large, retrospective, multinational study of patients with ANCA-AAV shows they may be at risk for CVEs. https://t.co/k9XPolEXKc https://t.co/0nxai3Eqe2
Check SSc-ILD Patients on Nintedinib for Malnutrition

During nintedanib treatment for interstitial lung disease associa

Dr. John Cush RheumNow

3 years 2 months ago
Check SSc-ILD Patients on Nintedinib for Malnutrition During nintedanib treatment for interstitial lung disease associated with SSc-ILD, clinicians prescribing the drug should be watchful for an unusual, indirect side effect, trial data suggested. https://t.co/5Q3xCwLvPa https://t.co/mGD3DCYZR0
RT @RheumNow: RheumNow LIVE VOTE Survey:
What do you need to better manage pre-clinical (at-risk) Rheumatoid arthritis?

Dr. John Cush RheumNow

3 years 2 months ago
RheumNow LIVE VOTE Survey: What do you need to better manage pre-clinical (at-risk) Rheumatoid arthritis? Please vote here >>https://t.co/lt38vJMEIA
2022 of fibromyalgia Year in review discusses possible causes (inflammation, gut dysbiosis, neuroinflammation), new Rx (

Dr. John Cush RheumNow

3 years 2 months ago
2022 of fibromyalgia Year in review discusses possible causes (inflammation, gut dysbiosis, neuroinflammation), new Rx (kinin antagonists, neurostimulation, mind-body Rx; but more needed on ketamine, vitamin D, and hormonal therapy https://t.co/IovNztH1kP https://t.co/fEVjO6ZW67
×